ABSTRACT Introduction: despite being extremely effective in some cases, up to 70% of patients with melanoma do not respond to anti-PD-1/PD-L1 (primary resistance) and many of the responders eventually
Supplemental Table 1. Treatment Patterns after Index Line for the Anti-programmed Cell Death-1-treated Patients with Advanced Melanoma Treated with a BRAF Therapy in the Index Line or Pri
Background: Combined treatment with BRAF -V600 and MEK inhibitors has significantly improved progression-free and overall survival of patients with BRAF -mutated melanoma. Pa
Angiogenesis and vasculogenic mimicry (VM) are thought to be the predominant processes ensuring tumor blood supply during the growth and metastasis of glioblastoma (GBM). Celastrol has potential anti-
